Business / Finance

RSS

Successful strategies for launching fixed dose combination products to market

The pharmaceutical industry is under constant pressure to produce new products and fixed dose combination therapies are one of the industry's strategies to offset lackluster pipelines and patent loss.

16 Jul 2011

Valeant to acquire Ortho Dermatologics

Valeant Pharmaceuticals International, Inc. announced today that Valeant's subsidiaries, Valeant Pharmaceuticals North America LLC (VPNA) and Valeant International (Barbados) SRL (VIB), have signed an agreement to acquire the assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc.

16 Jul 2011

Champions Oncology revenue increases 41% to $6.9 million for fiscal 2011

For its fiscal year 2011, Champions generated revenue of $6.9 million, an increase of $2 million or 41%, compared to fiscal year 2010.

16 Jul 2011

Medical Properties Trust announces results of cash tender offer for MPT Operating Partnership

Medical Properties Trust, Inc. and MPT Operating Partnership, L.P. today announced the expiration and final results of the previously announced cash tender offer to purchase any and all of the outstanding 9.25% Exchangeable Senior Notes due 2013 (CUSIP Number 55342NAG5) issued by the Operating Partnership at a purchase price of $1,185.29 for each $1,000 principal amount of the exchangeable notes purchased pursuant to the tender offer, plus accrued and unpaid interest to, but not including, the date of payment.

15 Jul 2011

First round of financing could make the intelligent bed a reality

At the end of May 2011, two "business angels" and a banking institute invested one million Swiss francs in Michael Sauter's company -compliant concept-. The successful end to this first round of financing is a milestone for the mechanical engineer and young entrepreneur. "This means that the intelligent bed can now become a reality," he says, joyfully.

15 Jul 2011

Hop-on acquires USAcig

Hop-on, Inc. announced today it acquired USAcig, Inc. for preferred stock.

15 Jul 2011

Nuvilex to move International Corporate HQ near FDA headquarters

Nuvilex, Inc. announced today it is in the final stages of locating its International Corporate Headquarters near the headquarters of the U.S. Food and Drug Administration.

15 Jul 2011

NeoStem to acquire Amorcyte

NeoStem, Inc., an international biopharmaceutical company, announced the signing of a definitive merger agreement whereby NeoStem will acquire Amorcyte, Inc., a development stage cell therapy company focusing on novel treatments for cardiovascular disease.

15 Jul 2011

ICON announces acquisition of Firecrest Clinical

ICON plc,, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the acquisition of Firecrest Clinical, a market-leading provider of technology solutions that boost investigator site performance and study management.

14 Jul 2011

inVentiv Health announces completion of PharmaNet acquisition

inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced it has completed the acquisition of PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries.

14 Jul 2011

Verastem raises $32 million to develop targeted cancer stem cell therapies

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced today that it has raised $32 million through a Series B financing. Proceeds from the financing will support ongoing research and development and will progress drug candidates into clinical development. The first candidate is projected to enter the clinic in 2012.

14 Jul 2011

DVS Sciences completes $14.6M series A financing

The Ontario Institute for Cancer Research (OICR) and DVS Sciences Inc., today announced that DVS Sciences has completed a $14.6 million series A financing.

14 Jul 2011

Vitrolife second quarter sales increase 19% to SEK 88 million

Vitrolife: Second quarter in brief. Sales growth increased by 31 percent in local currency in the second quarter. Sales amounted to SEK 88 (73) million, corresponding to an increase by 19 percent in SEK.

14 Jul 2011

Humira's early-line growth threatens Enbrel's future uptake in psoriatic arthritis

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that while Amgen/Pfizer's Enbrel was the most widely used tumor necrosis factor (TNF)-alpha inhibitor for recently treated psoriatic arthritis patients in the fourth quarter of 2010, Abbott's Humira has superseded Enbrel as an early-line TNF-alpha inhibitor for newly diagnosed psoriatic arthritis patients. Humira's early-line growth threatens Enbrel's future uptake in psoriatic arthritis.

14 Jul 2011

Orexo acquires Wagner Analysen Technik

Orexo AB has, through its subsidiary Kibion AB, acquired the German company Wagner Analysen Technik GmbH.

14 Jul 2011

Teva acquires Taiyo

Teva Pharmaceutical Industries Ltd. announced today that it has completed the acquisition of effectively 100% of the outstanding shares of Taiyo Pharmaceutical Industry Co. Ltd. for $934 million in cash.

14 Jul 2011

Apax Partners, CPPIB and PSP Investments to acquire KCI for $68.50 per share

Kinetic Concepts, Inc. today announced that it has entered into a definitive merger agreement under which a consortium comprised of funds advised by Apax Partners, together with controlled affiliates of Canada Pension Plan Investment Board and the Public Sector Pension Investment Board, will acquire KCI for $68.50 per share in cash in a transaction valued at $6.3 billion.

13 Jul 2011